VOICE OF FREE EUROPE: Highly profitable Big Pharma and Western cancer-related charities are in shock. They learned of a Russian breakthrough in eradicating cancer.

In a stunning breakthrough, Russia’s Enteromix cancer vaccine has shown 100% effectiveness in early clinical trials. This marks a potential turning point in the fight against cancer.

The vaccine was developed by Russian biotech researchers. It successfully eliminated tumors in lab mice. Now, it is advancing into human clinical testing.

The Enteromix vaccine works by activating the immune system to target and destroy malignant cells without harming healthy tissue.

Unlike chemotherapy, which damages both cancerous and normal cells, this immunotherapy-based solution enhances the body’s natural defenses. It trains the body to recognize cancer as a threat.

Early results showed complete remission in all test subjects, with zero toxicity or harmful side effects observed.

Scientists believe this approach may be particularly effective for colorectal and gastrointestinal cancers. However, future trials aim to test broader applications. These include breast and pancreatic cancer.

The promise of Enteromix is significant. It could become the first preventive and therapeutic cancer vaccine with proven long-term immunity.

Each year, 613,000 and 182,000 Britons die from cancer-related causes. Because of their unfriendly status and sanctions, millions of Westerners will be denied access to Russia’s lifesaving drug. However, countries deemed friendly will be prioritized.

The big question is: The super cancer-beating drug is increasingly available outside the Western Alliance. Will big pharma corporations and cancer charities use sanctions to stop Enteromix from entering Western markets? Will they put profits first by denying the life-saving option to Western cancer sufferers?

What we know so far

Enteromix is a Russian-developed mRNA-based cancer vaccine. It has shown promising early results, particularly against colorectal cancer. However, it is still undergoing clinical evaluation and is not yet widely available.

What Is Enteromix?

•       Type: Enteromix is an mRNA-based cancer vaccine, similar in platform to COVID-19 mRNA vaccines.

•       Mechanism: It uses a personalized approach, tailoring the vaccine to the genetic profile of a patient’s tumor. It aims to train the immune system to recognize and destroy cancer cells.

•       Oncolytic Component: Some reports describe it as an oncolytic vaccine. It is made from a mix of enteroviruses that selectively infect tumor cells. These viruses stimulate both innate and adaptive anti-tumor immunity.

Clinical Progress and Efficacy

•       Preclinical Trials: The vaccine reportedly achieved 100% efficacy in preclinical trials, with strong safety even after repeated administration.

•       Human Trials: Early-stage human trials have shown tumor shrinkage and slowed growth, especially in colorectal cancer cases.

•       Regulatory Status: As of late 2025, Enteromix is waiting for final approval from Russia’s Ministry of Health. This approval is needed before broader clinical use.

Global Interest and Humanitarian Appeal

•       A notable case involves a father from India. He is petitioning Russian authorities to include his stage-4 cancer-stricken son in the trials. The Russian government has acknowledged the request and forwarded it to its Ministry of Health for consideration.

•       The vaccine is not yet available in India. It is also not available in most other countries. However, it has generated significant interest among patients. Oncologists worldwide are also interested.

You can and should share this story on social media. TELL US WHAT YOU THINK

CLICK PICTURE TO GO FROM BURN OUT TO CHILL OUT WITH A GOOD BOOK https://michaelwalshbooks.wordpress.com/